Beam Therapeutics
NASDAQ: BEAM
Pioneering CRISPR base editing for precision genetic medicines to treat disease.
Pioneering CRISPR base editing for precision genetic medicines to treat disease.
Sector
Life SciencesCategory
TherapeuticsLocation
Cambridge, MAInitial Investment
Created 2018Beam Therapeutics (NASDAQ: BEAM) is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time.
“F-Prime played a critical role in establishing and growing Beam, helping us assemble our team and develop our vision to become the leading platform for precision gene editing. We are incredibly grateful for the team’s support for our mission to bring life-changing treatments to patients suffering from serious diseases.”
John Evans, CEO
